Hiroshi Tada

9PUBLICATIONS
52CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Respiratory diseasesPredictive and prognostic markersLiquid biopsiesEpidemiology not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jan 24, 2025
Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis.

Yutaka Yamamoto, Hiroji Iwata, Shigehira Saji

|Jan 09, 2025
Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.

Toshinari Yamashita, Shigehira Saji, Toshimi Takano

|Nov 09, 2024
Receptor for Hyaluronan Mediated Motility (RHAMM)/Hyaluronan Axis in Breast Cancer Chemoresistance.

Shiori Fujisawa, Kiyoshi Takagi, Mio Yamaguchi-Tanaka

|Oct 28, 2024
Clinicopathogenomic analysis of PI3K/AKT/PTEN-altered luminal metastatic breast cancer in Japan.

Hiroshi Tada, Minoru Miyashita, Narumi Harada-Shoji

|Sep 17, 2024
Nationwide survey of the secondary findings in cancer genomic profiling: survey including liquid biopsy.

Saki Shimada, Takahiro Yamada, Akari Minamoto

|Aug 23, 2024
Surgical and irradiated case of early breast cancer in a patient with Ehlers-Danlos syndrome.

Asumi Yamazaki, Hiroshi Tada, Yuki Muroyama

Pageof 2

Frequent Collaborators

2 joint publications

Satoshi Morita

2 joint publications

Minoru Miyashita

2 joint publications

Takashi Suzuki

2 joint publications

Masato Takahashi